EUCTR2017-000212-41-DE进行中（未招募）1 期
An Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2586881 in Participants with Pulmonary Arterial Hypertension - PH 2a, SD, DE, safety, PK/PD study of GSK2586881 in Pulmonary Arterial Hypertension pts
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participants are eligible to be included in the study only if all of the following criteria apply:
- •1. Participant must be between 18-75 years of age (inclusive), at the time of signing the informed consent
- •Type of Participant and Disease Characteristics
- •2. Documented diagnosis of PAH, defined as mPAP > 25 mmHg and PWP = 15 mmHg.
- •3. IPAH, HPAH, or PAH associated with collagen vascular disease or appetite suppressant use.
- •- Note: Those with portopulmonary hypertension or PVOD are not eligible for the study
- •4. World Health Organization (WHO) functional class I, II, or III, stable for at least 8 weeks prior to enrollment.
- •5. Hemodynamically stable on background therapy with no evidence of uncontrolled right heart failure (historic data), as determined by the investigator.
- •6. Six minute walk (6MW) distance, as performed at screening or within 6 months prior to screening, of = 100 meters and = 500 meters.
- •7. Mean BP of >60 mmHg
- •8. Receiving stable doses of one or more medications that are approved for treatment of PAH, including endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and/or prostanoids/prostacyclin receptor agonists, for a minimum of 12 consecutive weeks before enrollment.
- •NOTE: Anticoagulant therapy can be adjusted according to target INR
- •9. Diuretic dose stable for 8 weeks.
- •10. Body weight = 100 kg and body mass index (BMI) within the range 18-35 kg/m2 (inclusive).
- •11. Male and/or female (following confirmation of negative pregnancy test for WOCBP). Women who are pregnant or breastfeeding are excluded.
- •Informed Consent
- •12. Capable of giving signed informed consent as described in Appendix 3 (within the protocol) which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 23
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Medical Conditions
- •1. History of systemic hypotension, defined as systolic BP <90 mmHg and/or diastolic BP <50 mmHg.
- •2. Hospitalization for PAH associated deterioration in the previous 6 months.
- •3. Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities.
- •Concurrent disease or condition that may interfere with study participation or safety include bleeding disorders, arrhythmia, organ transplant, organ failure, current neoplasm, poorly controlled diabetes mellitus, and serious neurological disorders.
- •4. Complex repaired and unrepaired congenital heart disease.
- •5. Subjects with Eisenmenger physiology.
- •6. Alanine transferase (ALT) >2x upper limit of normal (ULN).
- •7. Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- •8. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •9. Estimated glomerular-filtration-rate (eGFR) <45mL/min/1.73m2.
- •10. QTc >480 msec or QTc > 500 msec in participants with bundle branch block.
- •-The QTc is the QT interval corrected for heart rate according to Bazett’s formula (QTcB), Fridericia’s formula (QTcF), and/or another method. It is either machineread or manually over-read.
- •-The specific formula used to determine eligibility and discontinuation for an individual participant should be determined prior to initiation of the study. In other words, several different formulas cannot be used to calculate the QTc for an individual participant and then the lowest QTc value used to include or discontinue the participant from the trial.
- •11. Any bleeding concerns as evidenced by INR >1.5 (in participants not receiving anticoagulation therapy) or platelet count <80,000.
- •12. Hb <10 g/dL
- •Prior/Concomitant Therapy
- •13. Sensitivity to any of the study treatments, or components thereof, or drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates participation in the study.
- •14. Any use of an ACE inhibitor or angiotensin receptor blocker or renin inhibitors within 14 days prior to dosing. Therapy can be stopped to enable inclusion if deemed safe by the participant’s treating physician.
- •Prior/Concurrent Clinical Study Experience
- •15. Use of any investigational product (IP) or device within 30 days prior to dosing, or known requirement for any investigational agent prior to completion of all scheduled study assessments.
- •Diagnostic assessments
- •16. Positive HIV antibody test.
- •17. Presence of Hepatitis B surface antigen (HBsAg) at screening.
- •18. Positive Hepatitis C antibody test result at screening or within 3 months prior to starting study treatment.
- •-NOTE: Participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C ribonucleic acid (RNA) test is obtained.
- •19. Positive Hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment.
- •-NOTE: Test is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing.
- •Other Exclusions
- •20. Participation i
研究者
相似试验
进行中（未招募）
1 期
Study to test a new drug to treat patients with Pulmonary Arterial Hypertension (PAH).Pulmonary arterial hypertensionEUCTR2017-000212-41-ESGlaxoSmithKline, S.A.24
已完成
1 期
An interventional study to evaluate the safety, tolerability (how well a substance is tolerated by participants), and Pharmacokinetics (PK, the measure of how the human body processes a substance), of different dosages of TTI-0102 when given to healthy participants as either a single oral dose, or as an oral dose give twice daily on one day (as a potential treatment for COVID-19), compared with a single oral dose of the marketed product Cystagon (registered trademark).ACTRN12621000131853Thiogenesis Therapeutics, Inc.12
进行中（未招募）
1 期
An Open-Label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)EUCTR2017-000327-27-Outside-EU/EEAIonis Pharmaceuticals, Inc.34
进行中（未招募）
1 期
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infectioCTIS2024-513938-38-00Immunocore Limited30
进行中（未招募）
1 期
Phase 1/2 study of IMC-M113V in virologically suppressed chronic HIV infectioEUCTR2021-002008-11-ESImmunocore Limited53